VYNE Therapeutics Inc. Cash Flow Statement
VYNE|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
VYNE Therapeutics Inc. used $34M in operating cash flow and negative free cash flow of $34M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$39.8M | -$28.5M | -$23.2M | -$73.3M | -$255.6M | -$74.2M | -$29.1M | -$14.1M |
| Depreciation & Amortization | $4.0K | $0 | $72.0K | $109.0K | $341.0K | $319.0K | - | - |
| Operating Cash Flow | -$34.0M | -$25.3M | -$29.2M | -$56.4M | -$137.1M | -$68.7M | -$28.2M | -$2.3M |
| Capital Expenditures | $117.0K | $0 | - | - | $113.0K | $567.0K | $27.0K | $31.0K |
| Free Cash Flow | -$34.1M | -$25.3M | - | - | -$137.2M | -$69.2M | -$28.2M | -$2.3M |
| FCF Margin | -6804.2% | -5976.6% | - | - | -653.5% | -1925.8% | - | - |